Ian C. Marschner

Camperdown, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

Journal: JCO clinical cancer informatics

Published: July 10, 2026

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: February 18, 2026

Reply to Sharifan: Are Nonsignificant Results Neutral, Inconclusive, or Negative? Likelihood Ratios Distinguish.

Reply to Sharifan: Are Nonsignificant Results Neutral, Inconclusive, or Negative? Likelihood Ratios Distinguish.

Journal: American journal of respiratory and critical care medicine

Published: February 08, 2026

ECPR eligible refractory out of hospital cardiac arrests - A post-hoc analysis of the EVIDENCE randomised controlled trial and Registry.

ECPR eligible refractory out of hospital cardiac arrests - A post-hoc analysis of the EVIDENCE randomised controlled trial and Registry.

Journal: Resuscitation

Published: November 19, 2025

Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.

Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.

Journal: BJU international

Published: November 05, 2025

Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.

Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 25, 2025

Beyond neutral trials in critical care: embracing statistical alternatives.

Beyond neutral trials in critical care: embracing statistical alternatives.

Journal: American journal of respiratory and critical care medicine

Published: August 16, 2025

Beyond Neutral Trials in Critical Care: Embracing Statistical Alternatives.

Beyond Neutral Trials in Critical Care: Embracing Statistical Alternatives.

Journal: American journal of respiratory and critical care medicine

Published: August 16, 2025

INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

Journal: JNCI cancer spectrum

Published: May 04, 2025

Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised Trial.

Inhaled Ciclesonide for Community-Based COVID-19: A Placebo-Controlled Randomised Trial.

Journal: Respirology (Carlton, Vic.)

Published: April 08, 2025

Platform trials: key features, when to use them and methodological challenges.

Platform trials: key features, when to use them and methodological challenges.

Journal: The Medical journal of Australia

Published: January 08, 2025

Expedited transfer from the scene for refractory out-of-hospital cardiac arrest in Australia: a prospective, multicentre, parallel, open label, randomised clinical trial.

Expedited transfer from the scene for refractory out-of-hospital cardiac arrest in Australia: a prospective, multicentre, parallel, open label, randomised clinical trial.

Journal: The Lancet. Respiratory medicine

Published: December 17, 2024

Showing 1-12 of 71

Last Updated: 09/26/2026